| Name | Title | Contact Details |
|---|
Watching your child struggle is hard. FSGC offers professional child counseling in Topeka to help them overcome their unique struggles.
We provide a strong network of convenient neighborhood hearing care centers across the country that continually strives to find innovative ways to serve you better. Our Hearing Care Professionals are passionate about helping people to hear better, applying a consistent process to determine the best recommendations for your hearing health. We provide free next day evaluations with professional recommendations based upon your inidiviudal hearing needs and lifestyle. We offer a walk-in, walk-out 2-week FREE trial with hearing aids that are right for you - plus the Connect Advantage, your assurance Connect Hearing will be there every step of the way. Headquartered in the Chicago area, we are a fast growing division of Sonova (SOON:US), the world`s leading provider of innovative hearing healthcare solutions.
Wagoner Community Hospital is one of the leading providers in Healthcare, Pharmaceuticals, and Biotech. It is based in Wagoner, OK. To find more information about Wagoner Community Hospital, please visit www.wagonerhospital.com
Ontario Long Term Care Association is a Markham, ON-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
More than 20,000 genes make us human. Genes control critical aspects of health and disease — but what controls our genes? Foghorn® Therapeutics ($FHTX) is developing therapies based on a system that directs which genes our cells express, and when, where, and in what order. By manipulating this system with our unique Gene Traffic Control™ platform, Foghorn will change how genes turn “on” and “off.” Unlike approaches that edit genes, this novel way of thinking will alter what our DNA has in store for us—and rewrite destiny for millions of people living with disease. With Gene Traffic Control™ Foghorn is pioneering a new, major class of drug targets to develop unprecedented therapies for cancer and other serious diseases. We have already validated multiple targets, are in the process of developing drug candidates in multiple types of cancer and are beginning to explore other diseases.